Model STAR-LLD -Chronic Lymphocytic Leukemia (Cll)

STAR-LLD is in development in two continuous delivery systems: subcutaneous and transdermal. STAR-LLD is being developed to establish the only IMiD (immunomodulatory drug) approved for CLL. CLL is the most common form of leukemia. Lenalidomide has been shown to be efficacious and well tolerated in CLL previous randomized controlled trials did not obtain an indication for the product. Even in the absence of a formal approval, NCCN guidelines recommend lenalidomide for the maintenance treatment of CLL. Flattening the plasma concentration curve by reducing the Cmax and increasing the Cmin during a dose interval, continuous delivery is expected to improve tolerability.